Hims & Hers Health (HIMS) shares surged over 12% on Monday. This rally marks the stock's strongest single-day performance in two months.
Investor optimism followed projections that the company's peptide expansion could generate $19 billion in annual revenue by 2030. Retail interest spiked alongside the news, with Stocktwits message volume increasing more than 2,000%.
Analyst reactions to the expansion remain mixed. Canaccord Genuity recently reiterated a Buy rating, labeling peptides a primary long-term growth driver. Conversely, Leerink reiterated a Market Perform rating on June 16. Leerink views the upcoming FDA advisory meeting regarding compounded peptides as a modest binary event.